Non alcoholic fatty liver disease is now recognised as the most common liver disease. insulin ressistance,
Increase serum free fatty acids and oxidants incorporate in the pathogenesis leading to a syndrome extended from Simple mild steatosis to steatohepatitis to cirrhosis.
The aim to evaluate the effect of orlistat on features of fatty liver disaese in addition to glucose and lipid profile.
This is A prospective study of 60 type2 diabetic obese patients had evidence of non alcoholic fatty liver disease on ultrasound examination followed for 4 months with orlistat therapy, and asses BMI, waist circumfrence, glucose control, liver function, lipid profile and ultrasound features before and after 4 months.
Orlistat therapy decrease BMI, liver size, echogenisity by U/S, and triglyceride level significantly and increase
HDL also significantly,but also decrease FPG, 2hPG, HbA1c, serum cholesterol,ALT and waist circumference with insignificant statistical value, while had no effect on prothrombin time and total serum protein.
Orlistat therapy is beneficial adjuvant therapy in obese type 2 diabetics , it reduce BMI, and U/S manifestations
of NAFLD, it also correct dyslipidemia and possibly had positive effect on glucose control and liver enzymes.